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Toronto, Ontario, Canada; Boston, Massachusetts; and Paris, FranceObjectives This study sought to evaluate the efﬁcacy of prasugrel versus clopidogrel in ST-segment
elevation myocardial infarction (STEMI) by the timing of percutaneous coronary intervention (PCI).
Background Treatment strategies and outcomes for patients with STEMI may differ when treated with
primary compared with secondary PCI.
Methods STEMI patients in the TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction 38)
were randomized to prasugrel or clopidogrel on presentation if primary PCI was intended or later
during secondary PCI. Primary PCI was deﬁned as within 12 h of symptom onset. The primary endpoint
was cardiovascular death, myocardial infarction (MI), or stroke. Because periprocedural MI is difﬁcult to
assess in the setting of STEMI, we performed analyses excluding these events.
Results Reductions in the primary endpoint with prasugrel versus clopidogrel (hazard ratio [HR]:
0.79; 95% conﬁdence interval [CI]: 0.65 to 0.97; p ¼ 0.022) were consistent between primary and
secondary PCI patients at 15 months (HR: 0.89; 95% CI: 0.69 to 1.13 vs. HR: 0.65; 95% CI: 0.46 to 0.93;
p interaction ¼ 0.15). However, a tendency toward a difference in treatment effect at 30 days (HR: 0.68;
95% CI: 0.54 to 0.87; p ¼ 0.002) was observed between primary and secondary PCI patients (HR: 0.81;
95% CI: 0.60 to 1.09 vs. HR: 0.51; 95% CI: 0.34 to 0.76; p interaction¼ 0.06). When periprocedural MI was
excluded, the efﬁcacy of prasugrel remained consistent among primary and secondary PCI patients at
30 days (HR: 0.53; 95% CI: 0.34 to 0.81 vs. HR: 0.44; 95% CI: 0.22 to 0.88; p interaction ¼ 0.68) and
15 months (HR: 0.76; 95% CI: 0.56 to 1.03 vs. HR: 0.75; 95% CI: 0.46 to 1.21; p interaction ¼ 0.96).
Conclusions The efﬁcacy of prasugrel versus clopidogrel was consistent irrespective of the timing
of PCI, particularly in preventing nonprocedural events. (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38;
NCT00097591) (J Am Coll Cardiol Intv 2014;7:604–12) ª 2014 by the American College of Cardiology
FoundationFrom the *Women’s College Research Institute and Cardiovascular Division, Department of Medicine, Women’s College Hospital,
University of Toronto, Toronto, Ontario, Canada; yTIMI Study Group, Cardiovascular Division, Department of Medicine,
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; and the zACTION Study Group, Institut de
Cardiologie, Université Paris 6, INSERM UMRS-1166, Hôpital Pitié-Salpêtri_ere (AP-HP), Paris, France. TRITON–TIMI 38
received funding from Eli Lilly and Company and Daiichi Sankyo Company Ltd. No additional funding for this analysis was
provided. Dr. Udell was supported in part by a Postdoctoral Research Fellowship from the Canadian Institutes of Health Research
(Ottawa, Ontario, Canada) and the Canadian Foundation for Women’s Health (Ottawa, Ontario, Canada). The TIMI Study
Group has received signiﬁcant research grant support from Eli Lilly and Daiichi Sankyo. Dr. Braunwald has received signiﬁcant
research grant support from Eli Lilly and Daiichi Sankyo; and lecture honoraria from Daiichi Sankyo. Dr. Antman has received
signiﬁcant research grant support from Eli Lilly and Daiichi Sankyo. Ms. Murphy has received research funding from Eli Lilly.
Dr. Montalescot and his research units have received signiﬁcant research grant support from Abbott Vascular, Accumetrics,
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 6 , 2 0 1 4 Udell et al.
J U N E 2 0 1 4 : 6 0 4 – 1 2 Prasugrel in STEMI by PCI Timing
605Primary percutaneous coronary intervention (PCI) is the
preferred therapy for patients presenting with ST-segment
elevation myocardial infarction (STEMI) (1,2). However,
when mechanical reperfusion is unavailable in an expe-
dited fashion, ﬁbrinolysis for those presenting with acute
STEMI is an alternative method of initial reperfusion
routinely used worldwide (1–5). Alternatively, some pa-
tients with STEMI may delay presentation from symptom
onset until they are outside of the recommended time
window for primary PCI or ﬁbrinolytic therapy (<12 h) but
may remain symptomatic with chest discomfort secondary
to myocardial ischemia or present with other high-risk
features (hemodynamic instability, congestive heart failure,
or arrhythmia) prompting a need for secondary PCI (1,2).See page 613
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STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial InfarctionThe beneﬁt of dual antiplatelet therapy with prasugrel, a
potent thienopyridine, compared with clopidogrel, was
demonstrated in moderate- to high-risk acute coronary
syndrome (ACS) patients undergoing planned PCI in the
TRITON–TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition
with Prasugrel–Thrombolysis In Myocardial Infarction 38)
(6) and appeared to have particular beneﬁt within those pa-
tients presenting with STEMI (7). However, the value of
more rapid, consistent, and effective P2Y12 receptor bloc-
kade among STEMI patients reperfused via primary
compared with secondary PCI is not well established. The
objective of this pre-speciﬁed subgroup analysis of the
TRITON–TIMI 38 trial was to report the efﬁcacy and safety
of prasugrel compared with clopidogrel in STEMI patients
according to the timing of PCI and to test the hypothesis that
the comparisons between clopidogrel and prasugrel would be
similar regardless of the timing of PCI.
Methods
Study patients. TRITON–TIMI 38 was a randomized,
multicenter, double-blind, controlled trial for which theAstraZeneca, Biotronik, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Fédération
Française de Cardiologie, Fondation de France, INSERM, Institut de France,
Medtronic, Menarini, Nanospheres, Pﬁzer, Roche, Sanoﬁ-Aventis, Stentys, Société
Française de Cardiologie, and The Medicines Company; and consulting fees from
AstraZeneca, Accumetrics, Bayer, Biotronik, Bristol-Myers Squibb, Boehringer-
Ingelheim, Duke Institute, Eli Lilly, Europa, GlaxoSmithKline, Iroko, Lead Up,
Medtronic, Menarini, Novartis, Pﬁzer, Roche, Sanoﬁ-Aventis, Springer, The Medi-
cines Company, TIMI Study Group, WebMD, and Wolters. S. A. Murphy has
received research funding from Eli Lilly. Dr Wiviott has received signiﬁcant research
grants from Arena, AstraZeneca, Bristol-Myers-Squibb, Daiichi Sankyo, Eisai, Eli
Lilly, Merck, and Sanoﬁ-Aventis; and consulting fees from Aegerion, Angelmed,
Arena, AstraZeneca, Boston Clinical Research Institute, Bristol-Myers-Squibb,
Daiichi Sankyo, Eisai, Eli Lilly, ICON Clinical, Janssen, and Xoma. Dr. Udell has
reported that he has no relationships relevant to the contents of this paper to disclose.
Manuscript received September 10, 2013; revised manuscript received December 11,
2013, accepted January 4, 2014.eligibility and exclusion criteria, methods, and results were
previously reported (6–8). In brief, 13,608 patients with
moderate- to high-risk ACS undergoing planned PCI were
randomized to prasugrel (n ¼ 6,813) or clopidogrel (n ¼
6,795) on a background of aspirin therapy. Among this
cohort, 3,425 patients presented with STEMI and ulti-
mately underwent PCI (Fig. 1). Patients who were enrolled
and underwent PCI within 12 h of symptom onset (n ¼
2,340) were considered to have received primary PCI. Pa-
tients who were enrolled and underwent PCI between 12 h
and 14 days after presentation for demonstrated recurrent
myocardial ischemia or as part of routine medical manage-
ment (n ¼ 1,085) were considered as having received sec-
ondary PCI. Patients were excluded from the trial if they had
an increased risk of bleeding, known intracranial pathology,
1 doses of a thienopyridine within 5 days before random-
ization, recent thrombolytic therapy (24 h for ﬁbrin speciﬁc,
48 h for nonﬁbrin speciﬁc), or
the inability or unwillingness to
provide informed consent.
Endpoints. The primary efﬁcacy
endpoint of the trial as well as
this analysis was the composite of
cardiovascular (CV) death, non-
fatal myocardial infarction (MI),
or nonfatal stroke at 15 months.
We also provide results at 30
days of follow-up, a time period
consistent with previous trials in
STEMI and with primary PCI.
Other efﬁcacy endpoints in-
cluded CV death, nonfatal MI,
urgent target vessel revasculari-
zation at 30 days, deﬁnite or
probable stent thrombosis (9),
and other cardiovascular events.
Key safety endpoints included
Thrombolysis In Myocardial Infarction (TIMI) major
bleeding that was unrelated to coronary artery bypass graft
(CABG) surgery. A net clinical beneﬁt endpoint was
deﬁned as the composite of all-cause death, nonfatal MI,
nonfatal stroke, or nonfatal TIMI major bleeding unrelated
to CABG surgery. Components of the primary endpoint
and key safety endpoints were adjudicated by an indepen-
dent clinical events committee whose members were blinded
to the assigned treatment. We further characterized the
diagnosis of recurrent MI by its timing and relationship to
PCI according to the universal deﬁnition classiﬁcation
scheme into periprocedural and nonprocedural MI, as pre-
viously reported (10–12). Speciﬁcs of deﬁnitions were pre-
viously published (8). A sensitivity analysis excluding
periprocedural MI was conducted because of the inherent
challenge of delineating a recurrent MI using cardiac bio-
markers in the setting of STEMI, in which a patient may
Figure 1. Study Flow Diagram
ACS ¼ acute coronary syndromes; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
elevation myocardial infarction; UA ¼ unstable angina.
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606present early in the trajectory of an increase in cardiac bio-
markers with limited additional clinical details or when
myocardial injury may be due in part to reperfusion injury
(13–16).
Statistical analysis. Baseline characteristics were summa-
rized and compared between patient groups using fre-
quencies and the Pearson chi-square test for categorical
variables and medians with interquartile range (IQR) and
the Wilcoxon rank-sum test for continuous variables. Cu-
mulative event rates for clinical endpoints were determined
using the Kaplan-Meier method and compared using the
log-rank test. Efﬁcacy comparisons were performed on an
intention-to-treat basis with the use of a Cox proportional
hazards model according to the time to the ﬁrst event. To
determine whether the randomized treatment effect was
modiﬁed according to PCI timing, we assessed interaction
terms to test for differential effect by PCI timing for each
outcome. The event rates, hazard ratio (HR), 2-sided 95%
conﬁdence intervals (CIs), and p interaction terms are re-
ported for each outcome according to PCI timing. Analyses
of procedural and nonprocedural MI were performed ac-
cording to the time to ﬁrst MI. A landmark analysis of the
primary endpoint from 3 days after randomization to the
end of the study among surviving STEMI patients was
performed as a further sensitivity analysis to exclude pro-
cedural MI events. All analyses were performed using
STATA software (version 10.1, StataCorp, College Sta-
tion, Texas). A threshold of p < 0.05 was considered
statistically signiﬁcant for all tests. Data analyses were
conducted independent of the trial sponsors by the TIMIstudy group, which had full access to the data and take
responsibility for its integrity.
Results
Among the 3,425 STEMI patients who underwent PCI,
2,340 (68%) received primary PCI and 1,085 (32%) received
secondary PCI (Fig. 1). The clinical characteristics of the
STEMI patient population according to PCI timing are
reported in Table 1. Overall, the median time from symp-
tom onset to randomization for STEMI patients was 6.0 h
(IQR: 2.9 to 28.0 h). Among the 68% of STEMI patients
who were managed with primary PCI, that time was 3.7 h
(IQR: 2.3 to 6.6 h), whereas among the 32% of patients who
were managed with secondary PCI, that time was signiﬁ-
cantly longer, 47.3 h (IQR: 25.7 to 86.2) (p < 0.0001).
Patients treated with primary PCI compared with secondary
PCI were more frequently enrolled from Eastern Europe
(35.9% vs. 14.0%), more frequently treated with study
medication before PCI (30.1% vs. 18.8%), and more
frequently treated with unfractionated heparin and glyco-
protein IIb/IIIa inhibitor therapy (Table 1). As expected,
patients managed with primary PCI less frequently had a
history of diabetes mellitus (16.8% vs. 24.0%) and previous
ﬁbrinolytic therapy (2.4% vs. 29.0%). Among patients with
previous ﬁbrinolytic therapy, the timing of previous ﬁbri-
nolysis was a median 1.7 days (IQR: 1.1 to 2.6 days) in
primary PCI patients compared with secondary PCI
patients with a median of 2.2 days (IQR: 1.5 to 4.1 days)
(p ¼ 0.0002). There were no meaningful differences in age,
Table 1. Baseline Characteristics
PCI Timing
Primary
(n ¼ 2,340)
Secondary
(n ¼ 1,085) p Value
Age, yrs 59 (52–68) 58 (50–67) 0.006
Female 548 (23.4) 224 (20.6) 0.07
Body weight, kg 80.0 (72.0–90.0) 81.0 (72.0–92.5) 0.02
Region
North America 443 (18.9) 308 (28.4) <0.0001
Western Europe 654 (27.9) 337 (31.1)
Eastern Europe 841 (35.9) 152 (14.0)
Other 402 (17.2) 288 (26.5)
History
Hypertension 1,140 (48.7) 563 (51.9) 0.08
Hypercholesterolemia 879 (37.6) 533 (49.1) <0.0001
Diabetes mellitus 393 (16.8) 260 (24.0) <0.0001
Tobacco use 1,053 (45.0) 513 (47.3) 0.21
Chronic renal disease 260 (11.4) 94 (8.8) 0.02
Myocardial infarction 245 (10.5) 104 (9.6) 0.43
Stroke or TIA 68 (2.9) 38 (3.5) 0.35
Anterior myocardial infarction 922 (39.4) 411 (37.9) 0.40
Treatment and procedures
Time from symptom onset to
randomization, h
3.7 (2.3–6.6) 47.3 (25.7–86.2) <0.0001
Timing of study drug
Before PCI 704 (30.1) 204 (18.8) <0.0001
During PCI 1,571 (67.1) 863 (79.5)
After PCI 28 (1.2) 8 (0.7)
Concomitant medication
at randomization
Aspirin 2,256 (96.4) 1,044 (96.2) 0.78
Statin 1,618 (69.1) 819 (75.5) 0.0001
ACE inhibitor 896 (38.3) 568 (52.4) <0.0001
Beta-blocker 1,339 (57.2) 790 (72.8) <0.0001
Stent type during index PCI
BMS (only) 1,554 (66.4) 545 (50.2) <0.0001
DES 666 (28.5) 492 (45.3) <0.0001
Antithrombin 0.0003
Unfractionated heparin 1,679 (71.8) 722 (66.5)
Low-molecular-weight heparin 150 (6.4) 95 (8.8)
Bivalirudin 23 (1.0) 25 (2.3)
Other or a combination 438 (18.7) 220 (20.3)
Glycoprotein IIb/IIIa inhibitor 1,549 (66.2) 651 (60.0) 0.0004
Fibrinolytic therapy 56 (2.4) 315 (29.0) <0.0001
Multivessel PCI 150 (6.5) 118 (11.0) <0.0001
Values are n (%) or median (interquartile range). Data for some characteristics are missing for
some patients.
ACE ¼ angiotensin-converting enzyme; BMS ¼ bare metal stent; DES ¼ drug-eluting stent;
PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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607body weight, infarct location, and previous stroke between
groups.
Effect of prasugrel on 30-day outcomes according to PCI
timing. The effect of prasugrel compared with clopidogrel
with respect to 30-day outcomes is shown in Figure 2A andOnline Table 1. Compared with clopidogrel, treatment
with prasugrel for 30 days among STEMI patients resul-
ted in a signiﬁcant reduction in the primary endpoint (HR:
0.68; 95% CI: 0.54 to 0.87; p ¼ 0.002) and CV death,
nonfatal MI, or urgent target vessel revascularization (HR:
0.75; 95% CI: 0.59 to 0.96; p ¼ 0.02). However, a ten-
dency toward a difference in treatment effect was observed
between primary and secondary PCI-managed patients for
the primary endpoint (HR: 0.81; 95% CI: 0.60 to 1.09 vs.
HR: 0.51; 95% CI: 0.34 to 0.76; p interaction ¼ 0.06) and
CV death, nonfatal MI, or urgent target vessel revascu-
larization (HR: 0.91; 95% CI: 0.67 to 1.23 vs. HR: 0.53;
95% CI: 0.35 to 0.79; p interaction ¼ 0.03), respectively.
This difference was primarily driven by an observed
reduction in risk of MI seen among secondary PCI-
managed patients. Compared with clopidogrel, the risk of
the development of MI was further reduced with prasugrel
in patients managed with secondary PCI at 30 days (risk of
MI among primary PCI–managed patientsdHR: 0.92;
95% CI; 0.65 to 1.31; secondary PCI–managed
patientsdHR: 0.45; 95% CI: 0.29 to 0.71; p interaction ¼
0.01) (Fig. 2A).
Other individual cardiovascular endpoints, including stent
thrombosis, showed consistent effects regardless of PCI
timing (all other p interactions > 0.05). By 30 days, there
was also no signiﬁcant difference in the risk of major
bleeding events unrelated to CABG surgery by PCI timing
(p interaction ¼ 0.68).
Effect of prasugrel on 15-month outcomes according to PCI
timing. The primary endpoint, spontaneous CV events
(primary endpoint excluding periprocedural MI), and pri-
mary safety endpoint for the entire study period by treatment
group among both primary and secondary PCI-managed
patients is shown in Figures 2B and 3. Major efﬁcacy and
safety endpoint results at 15 months are also presented in
Online Table 1. Compared with clopidogrel, treatment with
prasugrel resulted in a signiﬁcant reduction in the primary
endpoint among STEMI patients (HR: 0.79; 95% CI; 0.65
to 0.97; p ¼ 0.022). When treatment effect was analyzed
according to PCI timing, this reduction was consistent
among both primary and secondary PCI–managed patients
(HR: 0.89; 95% CI: 0.69 to 1.13 vs. HR: 0.65; 95% CI: 0.46
to 0.93; p interaction ¼ 0.15) (Fig. 2B). In addition,
treatment with prasugrel resulted in similar reductions in
other major efﬁcacy endpoints (all p interactions  0.05),
except for MI (primary PCI–managed patientsdHR;
0.91; 95% CI: 0.67 to 1.22; secondary PCI–managed
patientsdHR: 0.54: 95% CI: 0.36 to 0.82; p interaction ¼
0.046) (Fig. 2B).
With regard to safety, by 15 months, in STEMI patients
overall, few non-CABG–related TIMI major bleeding
events developed without a signiﬁcant difference between
randomized treatment groups (HR: 1.11; 95% CI: 0.70 to
1.77). Nevertheless, compared with clopidogrel, the risk of
Figure 2. Forest Plot of the Effect of Therapy on Major Efﬁcacy and Safety Endpoints Among STEMI Patients Managed by Primary or Secondary PCI
Shown are Kaplan-Meier estimates of the rate of major efﬁcacy and safety endpoints, (A) at 30 days, (B) at 15 months, according to study-group assignment stratiﬁed
by PCI timing at randomization. See Figure 1 for numbers of patients in the prasugrel, clopidogrel, all STEMI, primary PCI, and secondary PCI cohorts. yOdds ratio. p
Values for interaction are shown next to the respective event rates for each endpoint. C ¼ clopidogrel; CABG ¼ coronary artery bypass grafting; CI ¼ conﬁdence
interval; CV ¼ cardiovascular; HR ¼ hazard ratio; KM ¼ Kaplan-Meier; MI ¼ myocardial infarction; P ¼ prasugrel; PCI ¼ percutaneous coronary intervention;
TIMI ¼ Thrombolysis In Myocardial Infarction.
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608TIMI major bleeding events observed with prasugrel was
lower among patients managed with secondary PCI (HR:
0.39: 95% CI: 0.14 to 1.11) compared with primary PCI
(HR: 1.52; 95% CI: 0.87 to 2.65; p interaction ¼ 0.02)
(Fig. 3).
Effect of prasugrel on nonprocedural CV events according to
PCI timing. When the type of MI was further delineated, a
signiﬁcant interaction according to PCI timing between the
effect of prasugrel compared with clopidogrel was apparent
only for proceduralMI events (primary PCIdHR: 1.19; 95%
CI: 0.78 to 1.81; secondary PCIdHR: 0.54; 95% CI: 0.33
to 0.89; p interaction ¼ 0.02 at 30 days [Fig. 2A];
p interaction ¼ 0.03 at 15 months [Fig. 2B]). In contrast, areduction in nonprocedural MI was consistent among both
primary and secondary PCI–managed patients (30-day and
15-month p interaction was 0.29 and 0.57, respectively)
(Fig. 2). As a result, when the treatment effect was analyzed
post-hoc focusing on spontaneous primary endpoint events
according to PCI timing (CV death, nonprocedural MI,
stroke), signiﬁcant differences in risk reduction among
primary and secondary PCI–managed patients were no
longer present (30-day and 15-month p interactions were
0.68 and 0.96, respectively (Fig. 2). Consistent ﬁndings
were seen in landmark analyses of the primary endpoint
from day 3 to day 30 (primary PCIdHR: 0.47; 95% CI:
0.26 to 0.83; secondary PCIdHR: 0.55; 95% CI: 0.27 to
Figure 2. Continued
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6091.14; p interaction ¼ 0.72) and to the end of study (primary
PCIdHR: 0.79; 95% CI: 0.56 to 1.11; secondary
PCIdHR: 0.84; 95% CI: 0.51 to 1.38; p interaction ¼
0.84).
Discussion
The pathophysiology of STEMI is characterized by extensive
thrombosis, and patients with STEMI tend to be at high risk
of recurrent thrombotic complications after PCI. Therapeutic
strategies may differ depending on the timing and indication
for PCI. Thus, understanding the consistency of beneﬁt
of prasugrel according to the timing of PCI is clinically
relevant (1,2,17). Overall, we observed a beneﬁt of prasugrel
compared with clopidogrel in patients with STEMI.
The diagnosis of a recurrent MI is particularly difﬁcult in
STEMI patients managed with primary PCI because of
reliance on cardiac biomarkers, which are often increased atthe time of presentation or as a result of reperfusion injury
(14,16,18,19). The recognition of a periprocedural MI re-
quires disentangling a recurrent pattern of increased bio-
markers of myocardial ischemia from the evolution of the
patient’s initial cardiac biomarker pattern (14,15). As a
result, recommendations for the classiﬁcation of a peri-
procedural MI have evolved (10). Procedural MIs were
observed less frequently among primary PCI patients and
appeared to have less of a treatment effect. Many of these
recurrent events may be less clearly discernible from the
index MI and represent nonmodiﬁable events or “noise”
during early follow-up. However, when nonprocedural MI
events were evaluated by either exclusion of procedural
events or landmark analyses at day 3 after randomization,
composite efﬁcacy endpoints showed a consistent beneﬁt of
prasugrel. This secondary analysis of the TRITON–TIMI
38 trial is therefore informative because perception of a
difference in treatment effect by PCI timing involving
Figure 3. Kaplan-Meier Curves for Selected Endpoints Among Primary and Secondary PCI Patients Treated With Clopidogrel or Prasugrel
1) Primary study endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) among primary PCI patients (A) and secondary PCI patients (B).
2) Spontaneous primary study endpoint (cardiovascular death, nonprocedural myocardial infarction, or nonfatal stroke) among primary PCI patients (C) and secondary
PCI patients (D). 3) Thrombolysis In Myocardial Infarction major bleeding unrelated to CABG surgery among primary PCI patients (E) and secondary PCI patients (F).
Abbreviations as in Figure 2.
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610endpoints that included nonfatal MI may have appeared as a
result of the inherent difﬁculty in distinguishing a recurrent
primary procedural MI from one that develops later in the
course of therapy when the increase and decrease in cardiac
ischemia biomarkers is well established after initial STEMI
presentation.
Although it appears that the differential in assessment of
procedural MIs explains any treatment differences observed,
secondary PCI–managed STEMI patients may be a more
select patient population who have greater beneﬁt in thelong term from more potent antithrombotic therapy at the
time of PCI, with a more favorable risk balance for recurrent
ischemia and spontaneous bleeding (17,20–22). This may in
part reﬂect a treating physician’s ability to select patients for
invasive management who are at a low risk of bleeding;
however, further prospective conﬁrmation of this observa-
tion is required.
The timing of study drug administration was not rando-
mized in TRITON–TIMI 38, in contrast to the ACCOAST
(A Comparison of Prasugrel at PCI or Time of Diagnosis
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611of Non-ST Elevation Myocardial Infarction) trial, which
compared 2 strategies of timing of prasugrel initiation among
non–ST-segment elevation ACS patients (23). In TRITON,
it was mandated that the coronary anatomy had to be known
to be suitable for PCI before randomizing non–ST-segment
elevation ACS patients or medically managed STEMI
patients. In STEMI patients with either previously known
coronary anatomy amenable to PCI or planned primary PCI,
pre-treatment with study drug was permitted for up to 24 h
before PCI. Although a small subgroup of the primary
and secondary PCI STEMI patients were randomized to
study drug before PCI, caution is advised in attempting
to compare analyses of TRITON with the results of
ACCOAST. With the exception of procedural events, a
strategy of treatment with prasugrel after the coronary anat-
omy is deﬁned or in select STEMI patients undergoing pri-
mary PCI resulted in consistent reductions in ischemic events
at the expense of an increased risk of bleeding.
Study limitations. The limitations of this analysis warrant
consideration. Patients with high-risk ACS enrolled in
TRITON–TIMI 38 were intended for an invasive man-
agement strategy; however, the timing of PCI was not
mandated, nor was justiﬁcation of PCI timing completely
characterized. As a result, PCI timing was not random,
resulting in inherent heterogeneity between patients who
received primary PCI compared with those who received
secondary PCI. Nevertheless, randomized comparisons
within each subgroup remain valid. In addition, the w70%
frequency of primary PCI management among our STEMI
patients is similar to the frequency of use within the
PLATO (Platelet Inhibition and Patient Outcomes) trial
(24,25). Furthermore, because publication of the universal
deﬁnition of MI occurred after completion of the
TRITON–TIMI 38 trial, procedural MI was not evaluated
using these new deﬁnitions (11). However, adjudicators
remained blinded to study treatment assignment; thus, we
would not expect bias in treatment effect comparisons of
procedural or nonprocedural endpoint results. As well, a
small sample of primary PCI patients received ﬁbrinolysis
>24 h before randomization, likely because either reperfu-
sion failed and/or recurrent STEMI developed in these
patients. Sensitivity analyses excluding these patients resul-
ted in no material difference in either the primary or sec-
ondary results. Likewise, secondary PCI patients in routine
clinical practice may be treated with clopidogrel at the time
of ﬁbrinolytic therapy; however, this was not standard of care
at the time that TRITON–TIMI 38 was conducted (1).
Because patients pre-treated with clopidogrel were excluded
from TRITON, we cannot extrapolate our ﬁndings to that
clinical scenario. Finally, this secondary analysis of the
TRITON–TIMI 38 population involved further subgroup
comparisons for STEMI patients receiving primary or sub-
sequent PCI and treatment effect interactions; hence, these
data should be interpreted with caution.Conclusions
The majority of STEMI patients in an international trial
comparing the efﬁcacy and safety of more potent antiplatelet
therapy were managed with primary PCI, whereas one-third
of patients were managed with secondary PCI. Patients
with STEMI who were managed with PCI late after
presentation appeared to be a highly selected group who
derived long-term efﬁcacy from more potent antithrombotic
therapy with a more favorable risk balance for spontaneous
bleeding. Primary and secondary PCI–managed STEMI
patients demonstrated consistent efﬁcacy results when
treated with prasugrel compared with clopidogrel, except
regarding the development of procedural MI. When non-
procedural MIs were considered apart from procedural
events, the beneﬁt of prasugrel was consistent, irrespective
of the timing of PCI.
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